You have 9 free searches left this month | to do more

regorafenib

Regorafenib is a drug used to treat Metastatic Colorectal Cancer, Colorectal Neoplasms, and Hepatocellular Carcinoma. Regorafenib is being actively studied in 66 studies and prior, has been studied in 37.

Top SponsorsTop SitesTop Investigators
Academic and Community Cancer Research UnitedMemorial Sloan Kettering Cancer CenterJaw-Yuan Wang, MD, PhD
Memorial Sloan Kettering Cancer CenterCentre Leon BerardYeh Chun-Nan
Australasian Gastro-Intestinal Trials GroupMayo ClinicAdil Daud
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
F
Terminated
  • Colorectal Cancer
  • Regorafenib
  • +2 more
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
2022-01-10
Jan 10, 2022
S
Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • Regorafenib + sintilimab
  • Regorafenib
  • Guangzhou, Guangdong, China
    the Second Affiliated Hospital of Guangzhou Medical University
2022-02-10
Feb 10, 2022
C
Recruiting
  • Recurrent Glioblastoma
  • Regorafenib
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer institute, Case Comprehensive Ca
2022-03-11
Mar 11, 2022
W
Recruiting
  • Hepatocellular Carcinoma
  • TheraBionic
  • Regorafenib
  • Winston-Salem, North Carolina
    Wake Forest Baptist Comprehensive Cancer Center
2022-02-22
Feb 22, 2022
B
Not yet recruiting
  • HCC
  • +3 more
  • Regorafenib
  • cTACE/DEB-TACE-HAIC
  • (no location specified)
2021-08-28
Aug 28, 2021
H
Active, not recruiting
  • Colorectal Cancer
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
2021-12-28
Dec 28, 2021
C
Recruiting
  • Colo-rectal Cancer
  • Metastatic Cancer
  • Regorafenib
  • +3 more
  • Besançon, France
  • +1 more
2022-03-10
Mar 10, 2022
T
Completed
  • Metastatic Colorectal Cancer
  • Regorafenib
  • Taipei, Taiwan
    Taipei Veterans General Hospital
2021-07-21
Jul 21, 2021
P
Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Regorafenib
  • PD-1 inhibitor
  • Beijing, Beijing, China
    Hai-Tao Zhao
2021-09-15
Sep 15, 2021
D
Recruiting
  • Thyroid Cancer
  • Regorafenib
  • New Haven, Connecticut
  • +1 more
2022-02-18
Feb 18, 2022
U
Active, not recruiting
  • Metastatic Colorectal Cancer
  • Regorafenib
  • Rochester, Minnesota
  • +3 more
2021-10-05
Oct 5, 2021
K
Completed
  • Advanced and Metastatic Solid Tumor
  • Kashiwa, Chiba, Japan
    NationalCCHE
2021-04-23
Apr 23, 2021
C
Recruiting
  • Hepatocellular Carcinoma
  • regorafenib
  • Seongnam-si, Gyeonggi-do, Korea, Republic of
  • +1 more
2021-11-14
Nov 14, 2021
H
Completed
  • Cancer of the Bile Duct
  • Regorafenib
  • Tampa, Florida
  • +2 more
2021-09-20
Sep 20, 2021
F
Recruiting
  • Liver Metastases
  • Colorectal Cancer Metastatic
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
2021-09-25
Sep 25, 2021
F
Recruiting
  • Hepatocellular Carcinoma
  • Barcelona, Spain
  • +6 more
2022-03-15
Mar 15, 2022
A
Not yet recruiting
  • Ovarian Cancer
  • Serous Ovarian Cancer
  • Pittsburgh, Pennsylvania
    University of Pittsburgh Cancer Institute
2021-10-28
Oct 28, 2021
N
Active, not recruiting
  • Ovarian Neoplasms
  • Regorafenib
  • Singapore, Singapore
    National Cancer Centre Singapore
2021-04-27
Apr 27, 2021
A
Withdrawn
  • Metastatic Solid Malignancies
  • Locally Advanced Solid Malignancies
  • Regorafenib
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
2021-06-18
Jun 18, 2021
S
Terminated
  • Rectal Cancer
  • Regorafenib
  • +3 more
  • Basel, Switzerland
  • +6 more
2022-01-14
Jan 14, 2022
G
Recruiting
  • Colorectal Cancer
  • Pisa, PI, Italy
    U.O. Oncologia 2 Universitaria
2021-03-10
Mar 10, 2021
A
Not yet recruiting
  • Stage IB Hepatocellular Carcinoma AJCC v8
  • +2 more
  • Durvalumab
  • Regorafenib
  • Gainesville, Florida
  • +3 more
2022-02-07
Feb 7, 2022
S
Active, not recruiting
  • KRAS Gene Mutation
  • +3 more
  • Palo Alto, California
    Stanford University School of Medicine
2022-02-09
Feb 9, 2022
M
Completed
  • Advanced Cancers
  • Regorafenib
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2021-03-31
Mar 31, 2021
I
Active, not recruiting
  • Glioblastoma Multiforme
  • Castellana Grotte, BA, Italy
  • +9 more
2022-03-31
Mar 31, 2022